Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof

Details for Australian Patent Application No. 2008254279 (hide)

Owner Merial Limited Aventis Agriculture

Inventors Huber, Scot Kevin; Jacobs, Robert Toms; Soll, Mark David; Le Hir De Fallois, Loic Patrick; Lee, Hyoung Ik; Wilkinson, Douglas Edward

Agent FB Rice

Pub. Number AU-A-2008254279

PCT Pub. Number WO2008/144275

Priority 60/930,485 15.05.07 US

Filing date 12 May 2008

Wipo publication date 27 November 2008

International Classifications

C07D 249/18 (2006.01) Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

A01N 37/34 (2006.01) Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids - Nitriles

A01N 43/707 (2006.01) Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds

A61P 33/00 (2006.01) Antiparasitic agents

C07C 253/04 (2006.01) Preparation of carboxylic acid nitriles

C07C 255/42 (2006.01) Carboxylic acid nitriles

C07D 231/56 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

Event Publications

3 December 2009 PCT application entered the National Phase

  PCT publication WO2008/144275 Priority application(s): WO2008/144275

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008254291-Methods of genome installation in a recipient host cell

2008254273-Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival